毕得医药股价涨5.01%，国投瑞银基金旗下1只基金重仓，持有5.32万股浮盈赚取19.26万元

Group 1 - The core viewpoint of the news is that Bid Pharma has seen a stock price increase of 5.01%, reaching 75.90 CNY per share, with a total market capitalization of 6.898 billion CNY [1] - Bid Pharma focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - The Guotou Ruijin Healthcare Mixed A Fund holds 53,200 shares of Bid Pharma, accounting for 2.84% of the fund's net value, ranking as the ninth largest holding [2] - The fund has achieved a year-to-date return of 32.49%, ranking 2279 out of 8136 in its category [2] - The fund manager, Liu Zexu, has a tenure of 2 years and 71 days, with the best fund return during this period being 31.19% [3]